Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Can response duration after the first rituximab treatment be used in timing of rituximab retreatment?
van Herwaarden N, van der Maas A, Jansen TL, Dutmer EA, Hartkamp A, van Riel PL, Kievit W, van den Bemt BJ, den Broeder AA. van Herwaarden N, et al. Among authors: van den bemt bj, van der maas a, van riel pl. Scand J Rheumatol. 2013;42(3):251-2. doi: 10.3109/03009742.2013.765030. Epub 2013 Mar 16. Scand J Rheumatol. 2013. PMID: 23496283 No abstract available.
Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study.
den Broeder AA, van Herwaarden N, van der Maas A, van den Hoogen FH, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ. den Broeder AA, et al. Among authors: van vollenhoven rf, van den bemt bj, van herwaarden n, van den hoogen fh, van der maas a. BMC Musculoskelet Disord. 2013 Oct 24;14:299. doi: 10.1186/1471-2474-14-299. BMC Musculoskelet Disord. 2013. PMID: 24152421 Free PMC article. Clinical Trial.
Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N, den Broeder AA, Jacobs W, van der Maas A, Bijlsma JW, van Vollenhoven RF, van den Bemt BJ. van Herwaarden N, et al. Among authors: van vollenhoven rf, van den bemt bj, van der maas a. Cochrane Database Syst Rev. 2014 Sep 29;(9):CD010455. doi: 10.1002/14651858.CD010455.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2019 May 24;5:CD010455. doi: 10.1002/14651858.CD010455.pub3 PMID: 25264908 Updated. Review.
Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial.
van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, den Broeder AA. van Herwaarden N, et al. Among authors: van vollenhoven rf, van den bemt bj, van den hoogen fh, van der maas a. BMJ. 2015 Apr 9;350:h1389. doi: 10.1136/bmj.h1389. BMJ. 2015. PMID: 25858265 Free PMC article. Clinical Trial.
Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis.
van Herwaarden N, Bouman CA, van der Maas A, van Vollenhoven RF, Bijlsma JW, van den Hoogen FH, den Broeder AA, van den Bemt BJ. van Herwaarden N, et al. Among authors: van vollenhoven rf, van den bemt bj, van den hoogen fh, van der maas a. Ann Rheum Dis. 2015 Dec;74(12):2260-1. doi: 10.1136/annrheumdis-2015-207814. Epub 2015 Sep 4. Ann Rheum Dis. 2015. PMID: 26342093 No abstract available.
Disease activity-guided dose optimisation of adalimumab and etanercept is a cost-effective strategy compared with non-tapering tight control rheumatoid arthritis care: analyses of the DRESS study.
Kievit W, van Herwaarden N, van den Hoogen FH, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, van der Maas A, den Broeder AA. Kievit W, et al. Among authors: van vollenhoven rf, van den bemt bj, van herwaarden n, van den hoogen fh, van der maas a. Ann Rheum Dis. 2016 Nov;75(11):1939-1944. doi: 10.1136/annrheumdis-2015-208317. Epub 2016 Jan 13. Ann Rheum Dis. 2016. PMID: 26764260 Clinical Trial.
A multi-biomarker score measuring disease activity in rheumatoid arthritis patients tapering adalimumab or etanercept: predictive value for clinical and radiographic outcomes.
Bouman CAM, van der Maas A, van Herwaarden N, Sasso EH, van den Hoogen FHJ, den Broeder AA. Bouman CAM, et al. Among authors: van den hoogen fhj, van herwaarden n, van der maas a. Rheumatology (Oxford). 2017 Jun 1;56(6):973-980. doi: 10.1093/rheumatology/kex003. Rheumatology (Oxford). 2017. PMID: 28339738 Clinical Trial.
42 results